Design, synthesis and in vitro biological evaluation of a small cyclic peptide as inhibitor of vascular endothelial growth factor binding to neuropilin-1
Graphical abstract
Section snippets
Acknowledgments
This work was supported by National Science Centre (NCN) – Poland grant N204 350940 and co-financed by the EU from the European Regional Development Fund under the Operational Programme Innovative Economy, 2007–2013, and with the use of CePT infrastructure financed by the same EU program and a grant from the University of Warsaw – Poland for young researchers, no. 12000-501/86-DSM-107500. Molecular modelling was supported by Computational Grant G63-10 from the Interdisciplinary Centre for
References and notes (42)
- et al.
J. Biol. Chem.
(1991) - et al.
Biochem. Biophys. Res. Commun.
(1992) - et al.
Cancer Cell
(2007) - et al.
Cancer Lett.
(2016) - et al.
Drug Discovery Today
(2013) - et al.
Biochem. Biophys. Res. Commun.
(2001) - et al.
J. Biol. Chem.
(2006) - et al.
Life Sci.
(2006) - et al.
Peptides
(2007) - et al.
Drug Discovery Today
(2010)
Curr. Opin. Chem. Biol.
Bioorg. Med. Chem.
J. Controlled Release
Cell
J. Biol. Chem.
N. Eng. J. Med.
Oncotarget
Nat. Med.
Mol. Biol. Cell
Circ. Res.
J. Pathol.
Cited by (21)
Structure-activity relationship studies and biological properties evaluation of peptidic NRP-1 ligands: Investigation of N-terminal cysteine importance
2023, Bioorganic and Medicinal ChemistryTargeting VEGF–neuropilin interactions: a promising antitumor strategy
2019, Drug Discovery TodayCitation Excerpt :In this cyclic peptide, a lactam bond is formed between the side chains of lysine in position 1 and glutamine in position 3, while the crucial C-terminal arginine remains exocyclic. Significantly increased in vitro activity was observed with H-c[Lys-Pro-Glu]-Arg-OH compared with A7R [44]. Structure–activity relationship studies indicated that the ring size, rather than the position of the lactam bond, was more important for maintaining the strong inhibitory effect of H-c[Lys-Pro-Glu]-Arg-OH [45].
Branched pentapeptides as potent inhibitors of the vascular endothelial growth factor 165 binding to Neuropilin-1: Design, synthesis and biological activity
2018, European Journal of Medicinal ChemistryCitation Excerpt :Another approach envisages blocking the binding site at the receptor surface by competitive inhibitors of VEGF165 thus preventing the NRP-1-signaling pathway of this growth factor. The so far proposed inhibitors include cyclic [19–22] or linear [23–29] peptides/peptidomimetics and small molecules [30–37]. In the recent years an increase of a number approvals for peptides therapeutics was observed [38].
New peptide MY1340 revert the inhibition effect of VEGF on dendritic cells differentiation and maturation via blocking VEGF-NRP-1 axis and inhibit tumor growth in vivo
2018, International ImmunopharmacologyCitation Excerpt :Targeting this interaction has long been proposed as a validated approach to fight against angiogenesis-dependent diseases including cancer. Several attractive anti-NRP-1 antibodies, peptide and peptidomimetic drug-candidates or hits have been developed as anti-angiogenic drugs thus far [25,26]. However, although clinical and murine studies have described that new drugs interfering with VEGF-NRP1 interaction enhanced the antitumor effects via antiangiogenic effects, effects on the maturation and activation of DCs are incompletely understood [28,51].
Design and applications of cyclic peptides
2018, Peptide Applications in Biomedicine, Biotechnology and BioengineeringStructure-activity relationship study of tetrapeptide inhibitors of the Vascular Endothelial Growth Factor A binding to Neuropilin-1
2017, PeptidesCitation Excerpt :Several groups have studied different NRP-1/VEGF165 inhibitors. These included monoclonal antibodies [22], peptides [23–29], and small molecules [30–34]. Among peptides, an important result was the discovery (via phage display library screening) of a heptapeptide ATWLPPR (A7R) that in vivo decreases breast cancer angiogenesis and growth [35–37].